Interview With Invent Diagnostica GmbH
Interview with the Biospecimen Supplier Invent Diagnostica GmbH
in.vent Diagnostica GmbH has been a key player in the biospecimen industry for over 20 years, providing high-quality samples to support researchers. Focused on innovation, quality, and precision, in.vent Diagnostica operates a large biobank, enabling advancements in the life sciences. Their commitment to customer satisfaction and collaboration with partners has proved their standing as a reliable and innovative force in the market.
We had the pleasure of speaking with Mr. Robin Schmalfuss from in.vent Diagnostica to discuss their journey, operations, and valuable partnership with Central BioHub.
Question 1: Can you briefly introduce Invent Diagnostica GmbH and its journey in the biospecimen industry?
Robin: At in.vent Diagnostica GmbH, we have been committed to advancing diagnostics through the supply of high-quality biospecimens for over 20 years. Our journey began with a focus on providing essential human biological materials to support IVD (In Vitro Diagnostics) companies in the development of accurate and reliable diagnostic tools. Today, we operate a large biobank and are proud to supply biospecimens that drive innovation across the diagnostic landscape. From the start, our goal has been to facilitate groundbreaking research and development in the health sector, with an unwavering focus on quality, precision, and customer satisfaction.
Question 2: If you could describe Invent Diagnostica GmbH in three words, what would they be and why?
Robin: We are human. These three words reflect our commitment to putting people at the heart of everything we do. Whether it’s the patients who donate biospecimens, our partners, or the end-users of the diagnostic tools developed from our specimens, we aim to make a tangible difference in human lives. Our work is rooted in a human-centered approach to health and research.
Question 3: What product categories do you specialize in?
Robin: We specialize in the collection and provision of high-quality human biospecimens, including serum, plasma, urine, and other biological fluids, for use in IVD research and development. These biospecimens are essential for validation, calibration, and research, supporting both small-scale projects and large diagnostic studies. Our offerings also extend to disease-state and normal-range biospecimens, tailored to meet specific client requirements.
Question 4: What role has your 8-year partnership with Central BioHub played in your company’s growth?
Robin: Our collaboration with Central BioHub has been pivotal. Over the last eight years, we’ve seen an increasing demand for small volume biospecimens, and our partnership with Central BioHub has allowed us to efficiently manage this demand. By leveraging CBH's global platform, we’ve been able to access a wider audience and optimize the sales of our biospecimens. This partnership has not only provided a stable revenue stream but also allowed us to focus on our larger, strategic projects while ensuring that smaller orders are seamlessly fulfilled.
Question 5: What are the key benefits of working with Central BioHub for your company?
Robin: Working with Central BioHub provides us with several key benefits. First, their advanced digital platform streamlines the sales process for small-volume biospecimens, freeing us to focus on larger-scale endeavors. Their global reach connects us with a diverse client base, expanding our market access. Finally, the close and responsive communication we’ve developed with the company allows us to stay agile, addressing market needs and customer requirements quickly. Together, we ensure high standards of quality and service.
Question 6: Can you describe communication with Central BioHub? What are the key factors?
Robin: Communication with Central BioHub is open, direct, and continuous. We maintain regular exchanges to stay aligned on everything from operational updates to customer feedback. Transparency is key—we collaborate closely on improving workflows and addressing any challenges that arise. Flexibility and responsiveness also play a significant role, enabling us to fine-tune our offerings to meet market demands.
Question 7: How do you see your partnership with Central BioHub evolving in the future?
Robin: We see our partnership growing even stronger as both companies continue to innovate. With Central BioHub, we plan to enhance the digital infrastructure for even smoother order processing, ensuring that our biobank is fully integrated into their system. We also foresee expanding our offerings, perhaps moving into new categories of biospecimens as market demand evolves. Ultimately, we envision a future where we not only maintain our close relationship but also help set new industry standards together.
Question 8: If you could make one change to the biospecimen industry to drive progress, what would it be?
Robin: If we could make one change, it would be to increase industry-wide collaboration in data transparency and harmonization. By creating unified standards for biospecimen data and ensuring greater access to quality information, we could accelerate research outcomes and drive innovation in diagnostics. It’s about working together across organizations to reduce barriers to scientific discovery.
We would like to thank Robin for his valuable insights and for taking the time to share in.vent Diagnostica’s journey and expertise with us. Robin’s thoughtful answers reflect the depth of our collaboration and the mutual commitment to excellence. As she thoughtfully stated, “Customer satisfaction is a joint effort,” underscoring the importance of strong partnerships and shared goals in delivering the best products and services to clients worldwide.
Central BioHub - Order biospecimens online.